China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD 20.9 million) in an angel financing round. The round was led by Emerging Technology Partners (ETP) and Redhill Capital, with contributions from CASI Pharmaceuticals Inc. (NASDAQ: CASI). The proceeds will be used for a clinical trial filing for its drug candidate PAT-A001 in China and the US, application of the precision typing platform HDPM, and development of novel therapies targeting autoimmune and inflammatory diseases.
Company Overview
Founded in 2022, Tianshi Tongda boasts a precision typing platform HDPM for autoimmune diseases. The company integrates multi-omics technology, single-cell technology, and big data analysis to accelerate drug development and personalized medication.-Fineline Info & Tech
